Trial Profile
A retrospective,cohort study to evaluate the effects of Verteporfin photodynamic therapy combined with intravitreal Ranibizumab or Bevacizumab in treatment of choroidal neovascularisation in chronic central serous chorioretinopathy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Apr 2017
Price :
$35
*
At a glance
- Drugs Verteporfin (Primary) ; Bevacizumab; Ranibizumab
- Indications Choroidal neovascularisation
- Focus Therapeutic Use
- 08 Apr 2017 New trial record